<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871464</url>
  </required_header>
  <id_info>
    <org_study_id>2019-P2-153-02</org_study_id>
    <nct_id>NCT04871464</nct_id>
  </id_info>
  <brief_title>Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease</brief_title>
  <official_title>Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter randomized double-blind placebo-controlled study. The research&#xD;
      content is 1. The improvement effect of Bifidobacterium triple viable capsules（BIFICO） on&#xD;
      motor symptoms and constipation and sleep in mild to moderate Parkinson's disease and the&#xD;
      safety of the study; 2. the mechanism of the improvement effect of intestinal microecological&#xD;
      changes on motor and constipation symptoms in mild to moderate Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter randomized double-blind placebo-controlled study that included 240&#xD;
      patients with primary PD with modified H-Y stage 1-3, randomly divided into treatment and&#xD;
      placebo control groups; On the basis of the original PD medication, the treatment group was&#xD;
      given bifidobacterium triple viable capsules (BIFICO) and the control group was given&#xD;
      placebo; Patients who met the diagnosis of constipation were given Macrogol 4000 powder and&#xD;
      /or Enema glycerine as a rescue medicine, and the observation period was 12+12 weeks.&#xD;
&#xD;
      All subjects underwent the World Movement Disorders Society Parkinson's Disease Comprehensive&#xD;
      Rating Scale (MDS-UPDRS), Rome IV Constipation Diagnostic Scale, Cleveland Rating Scale,&#xD;
      Parkinson's Disease Sleep Scale-2 (PDSS-2), and General Clinical Outcome Inventory (CGI)&#xD;
      scores before and after treatment, and also recorded the patients' single bowel movement time&#xD;
      and the use of Macrogol 4000 powder and Enema glycerine , to investigate the improvement&#xD;
      effect of Bifido on motor symptoms and non-motor symptoms in PD patients. For the above&#xD;
      patients, stool and blood samples were collected at the time of enrollment and at 12 weeks of&#xD;
      observation.&#xD;
&#xD;
      At the same time,120 age-and gender-matched healthy adults without constipation were&#xD;
      recruited, and their stool and blood samples were collected; the stool samples of PD patients&#xD;
      before and after treatment and healthy controls were subjected to the determination of fecal&#xD;
      flora 16S DNA abundance. Stool samples of 10 PD patients and 10 healthy controls were taken&#xD;
      from each group for metagenomic sequencing. Detection of small molecule metabolites,&#xD;
      PD-related genes in blood. To investigate the effect of BIFICO on levodopa pharmacokinetics,&#xD;
      levodopa pharmacokinetic measurements will be performed at Friendship Hospital. For patients&#xD;
      who agree to participate and sign the informed consent form, blood specimens will be&#xD;
      collected consecutively at Visit 2 and Visit 11 after taking Levodopa and Benserazide&#xD;
      Hydrochloride Tablets for levodopa blood concentration measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study is double blind design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale(MDS-UPDRS)Ⅱ+Ⅲ</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part Ⅱ：This measures the motor aspects of activity of daily living and consists of 13 items with scores between 0- 52. Part Ⅲ：This measures the severity of motor symptoms using 18 items (score 0-72). Higher score indicates high severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of MDS-UPDRS II+III total score change &lt;3 points</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients whose total score of MDS-UPDRS Ⅱ+Ⅲ changed from baseline by less than 3 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale(MDS-UPDRS)Ⅱ+Ⅲ</measure>
    <time_frame>24 weeks</time_frame>
    <description>Part Ⅱ：This measures the motor aspects of activity of daily living and consists of 13 items with scores between 0- 52. Part Ⅲ：This measures the severity of motor symptoms using 18 items (score 0-72). Higher score indicates high severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of MDS-UPDRS II+III total score change &lt;3 points</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients whose total score of MDS-UPDRS Ⅱ+Ⅲ changed from baseline by less than 3 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale(MDS-UPDRS) part Ⅰ</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Assessment of non-motor symptoms of daily life.There are 13 questions, 6 questions in Part 1 A to be completed by the rater and 7 questions in Part 1 B to be completed by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleveland Constipation Score（ CCS），Rome Ⅲ Diagnostic Criteria for Constipation</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Constipation improvement was assessed using the Cleveland Constipation Score Change, an 8-question scale with scores ranging from 0 to 30. Evaluate the improvement rate of constipation according to the changes in the proportion of patients who meet the Rome III constipation diagnostic criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Sleep Scale-2 (PDSS-2):</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Use Parkinson's Disease Sleep Scale-2 (PDSS-2) to assess the patient's sleep improvement. The scale has 15 questions，the higher the score, the worse the sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-severity of illness</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Change in scale scores from baseline to assess change in severity of patient's condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-global improvement</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Evaluate the efficacy of patients based on their current condition compared to the time of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term medication safety</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Compare the incidence of adverse reactions between the two groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonian Disorders</condition>
  <condition>Basal Ganglia Diseases</condition>
  <condition>Brain Diseases</condition>
  <condition>Movement Disorders</condition>
  <condition>Neurodegenerative Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy subjects without constipation matched for age and sex to PD subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules</intervention_name>
    <description>Oral</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>BIFICO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-80 years old, both male and female;&#xD;
&#xD;
          -  Patients with primary Parkinson's disease who meet the 2015 MDS clinical diagnostic&#xD;
             criteria; PD with modified Hoehn-Yahr stage 1-3 and MDS-UPDRS II+III score ≥ 14 and no&#xD;
             significant off periods or off periods ≤ 1.5 hours per day (excluding morning motor&#xD;
             inability);&#xD;
&#xD;
          -  Pre-enrollment therapeutic medications included Levodopa and Benserazide Hydrochloride&#xD;
             Tablets, and all Parkinson's disease medications were unadjusted and motor symptoms&#xD;
             were stable for 28 days prior to enrollment;&#xD;
&#xD;
          -  No probiotic or/and prebiotic (including lactulose) and antibiotic therapy for 60 days&#xD;
             prior to enrollment, and if so, a 60-day washout period;&#xD;
&#xD;
          -  Understand and agree to follow the study protocol, agree to be enrolled and sign the&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parkinson's superimposed syndrome and secondary Parkinson's syndrome, such as multiple&#xD;
             system atrophy, progressive supranuclear palsy, etc.；&#xD;
&#xD;
          -  Taking any probiotic or prebiotic (including lactulose) within 60 days prior to&#xD;
             enrollment; having inflammation at any site and using any antibiotic within 60 days&#xD;
             prior to enrollment; or having blood leukocytes above the upper limit of normal at&#xD;
             screening；&#xD;
&#xD;
          -  Combined endocrine disorders, such as history of diabetes or fasting glucose ≥ 7.8&#xD;
             mmol/L, hyper- or hypothyroidism, adrenal tumors, abnormal pituitary function, etc.；&#xD;
&#xD;
          -  Comorbid other neurological disorders, such as cognitive impairment, Mini-Mental State&#xD;
             Examination（MMSE） scale score &lt;24; severe anxiety states and/or severe depressive&#xD;
             states (Hamilton Depression Inventory-17 item score &gt;17, Hamilton Anxiety Scale score&#xD;
             ≥14, or being treated with antidepressant anxiety medication); malignancy, spinal cord&#xD;
             lesions, epilepsy, autonomic disorders (urinary retention, urinary incontinence, or&#xD;
             upright hypotension , blood pressure drop ≥30/15 mmHg at any time point within 5&#xD;
             minutes of uprightness), etc.; new cerebrovascular disease or sequelae of severe&#xD;
             cerebrovascular disease within 6 months, which affects the assessment；&#xD;
&#xD;
          -  Gastrointestinal tumors, history of inflammatory bowel disease, other acute and&#xD;
             chronic inflammation of the gastrointestinal tract (including acute attacks of&#xD;
             cholecystitis) within 3 months；&#xD;
&#xD;
          -  History of gastrointestinal surgery (excluding endoscopic resection of&#xD;
             gastrointestinal benign polyps, appendicitis resection) or constipation caused by&#xD;
             surgery；&#xD;
&#xD;
          -  History of anal fissure, perianal abscess, irreversible anal prolapse, pelvic trauma；&#xD;
&#xD;
          -  Severe cardiovascular disease (such as congestive heart failure with a heart function&#xD;
             classification of Ⅲ-Ⅳ by the American Heart Association, a history of myocardial&#xD;
             infarction within 6 months, etc.);&#xD;
&#xD;
          -  Severe liver and kidney dysfunction with glutamate-pyruvate transaminase, aspartate&#xD;
             transaminase and total bilirubin 1.5 times higher than the upper limit of normal;&#xD;
             serum creatinine 1.5 times higher than the upper limit of normal;&#xD;
&#xD;
          -  Pregnant and lactating women or women of childbearing age (40-60 years) who are human&#xD;
             chorionic gonadotropin (HCG)-positive;&#xD;
&#xD;
          -  Known allergy to test drugs or related products;&#xD;
&#xD;
          -  People with a history of drug abuse or alcohol dependence;&#xD;
&#xD;
          -  Those who have participated in other clinical trials within 3 months prior to&#xD;
             enrollment;&#xD;
&#xD;
          -  Refusal to enroll and inability to cooperate with the investigator; patients judged by&#xD;
             the investigator to be unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houzhen Tuo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Houzhen Tuo, PhD</last_name>
    <phone>+8613683628005</phone>
    <phone_ext>13810468301</phone_ext>
    <email>tuohouzhen@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miao Jin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhaoxia Wang, PhD</last_name>
      <phone>+86 13681495953</phone>
      <email>drwangzx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houzhen Tuo, PhD</last_name>
      <phone>+8613683628005</phone>
      <email>tuohouzhen@ccmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Feng, PhD</last_name>
      <email>happyft@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Biao Chen, PhD</last_name>
      <email>pbchan06@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weizhong Xiao, PhD</last_name>
      <email>xiguataoxiao@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haibo Chen, PhD</last_name>
      <phone>13910622285</phone>
      <email>chenhbneuro@263.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Han Wang, PhD</last_name>
      <email>wanghanpumch@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuang Liu, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Peng, PhD</last_name>
      <email>Penghua106@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016 Dec 1;167(6):1469-1480.e12. doi: 10.1016/j.cell.2016.11.018.</citation>
    <PMID>27912057</PMID>
  </reference>
  <reference>
    <citation>Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, Pinelli G, Privitera G, Cesari I, Faierman SA, Caccialanza R, Pezzoli G, Cereda E. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology. 2016 Sep 20;87(12):1274-80. doi: 10.1212/WNL.0000000000003127. Epub 2016 Aug 19.</citation>
    <PMID>27543643</PMID>
  </reference>
  <reference>
    <citation>Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z. Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019 Jun;38(3):1031-1035. doi: 10.1016/j.clnu.2018.05.018. Epub 2018 Jun 1.</citation>
    <PMID>29891223</PMID>
  </reference>
  <reference>
    <citation>Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron. 2019 Aug 21;103(4):627-641.e7. doi: 10.1016/j.neuron.2019.05.035. Epub 2019 Jun 26.</citation>
    <PMID>31255487</PMID>
  </reference>
  <reference>
    <citation>Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, Chen SD, Xiao Q. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. 2018 May;70:194-202. doi: 10.1016/j.bbi.2018.02.016. Epub 2018 Mar 2.</citation>
    <PMID>29501802</PMID>
  </reference>
  <reference>
    <citation>Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015 Mar;30(3):350-8. doi: 10.1002/mds.26069. Epub 2014 Dec 5.</citation>
    <PMID>25476529</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Houzhen Tuo</investigator_full_name>
    <investigator_title>Vice-Director of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Basal Ganglia Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

